Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.
暂无分享,去创建一个
[1] M. Piver,et al. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] H. Lazarus,et al. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. , 1987, Seminars in oncology.
[3] S. Ménard,et al. Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.
[4] A. Thor,et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.
[5] N. Hacker,et al. Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study , 1985 .
[6] S. Howell,et al. Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Morgan Lr. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. , 1985 .
[8] R. Giuntoli,et al. The second-look celiotomy in ovarian cancer. , 1984, Gynecologic oncology.
[9] J. Wharton,et al. Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. , 1984, American journal of obstetrics and gynecology.
[10] Y. Tan,et al. Enhancement of actinomycin D- and cis-diamminedichloroplatinum(II)-induced killing of human fibroblasts by human beta-interferon. , 1983, Cancer research.
[11] J. Arseneau,et al. Cis‐platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens , 1983, Cancer.
[12] C. Cohen,et al. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. , 1983, American journal of obstetrics and gynecology.
[13] C. Myers,et al. Pharmacology of intraperitoneal chemotherapy. , 1983, Cancer investigation.
[14] R. Olshen,et al. Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.
[15] R. Ozols,et al. Phase I and Pharmacological Studies of Adriamycin Administered Intraperitoneally to Patients with Ovarian Cancer , 1982, Cancer research.
[16] R. Buchanan,et al. Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum‐based combination , 1982, Cancer.
[17] R. Bast,et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.
[18] S. Howell,et al. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. , 1981, The Journal of clinical investigation.
[19] S. Vogl,et al. Toxicity of Cis‐diamminedichloroplatinum II given in a two‐hour outpatient regimen of diuresis and hydration , 1980, Cancer.
[20] R. Fisher,et al. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. , 1978, The New England journal of medicine.
[21] V. Devita,et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. , 1978, Cancer treatment reports.